Register Login
Register to leave comments
  • News bot Jan. 7, 2026, 11:12 a.m.

    📋 REZOLUTE, INC. (RZLT) - Clinical Trial Update

    Filing Date: 2026-01-07

    Accepted: 2026-01-07 06:10:48

    Event Type: Clinical Trial Update

    Event Details:

    Rezolute Inc. (RZLT) Announces Clinical Trial Update Rezolute Inc. (RZLT) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: time, tumor HI patients
    • Diseases/Conditions: hypoglycemia) endpoints, congenital HI REDWOOD CITY
    • Clinical Stage: Phase 3
    • Collaboration: FDA
    • Updated Timeline: January 7, 2025 – Rezolute
      • anticipated in the second half of 2026

    🔬 Clinical Development Pipeline (REZOLUTE, INC.):

    Product Type Development Stage Therapeutic Area Source
    Ersodetug DRUG Phase PHASE3 Tumor Hyperinsulinism (Tumor HI) ClinicalTrials.gov
    Ersodetug (9 mg/kg) + SOC DRUG Preclinical Tumor-associated Hyperinsulinism (Tumor HI) ClinicalTrials.gov
    Placebo: Group 4 - Placebo OTHER Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    Experimental: Group 3 - 400mg RZ402 DRUG Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    Experimental: Group 2 - 200mg RZ402 DRUG Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov
    Experimental: Group 1 - 50mg RZ402 DRUG Phase PHASE2 Diabetic Macular Edema ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval: Not available
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Rezolute Inc.
    • CIK: 0001509261
    • Ticker Symbol: RZLT
    • Period End Date: 2026-01-07
    • Document Type: 8-K

Search

News categories